|1.||Giranda, Vincent L: 9 articles (02/2010 - 05/2007)|
|2.||Liu, Xuesong: 6 articles (12/2009 - 05/2007)|
|3.||Shi, Yan: 6 articles (12/2009 - 05/2007)|
|4.||Rubinstein, Larry: 5 articles (09/2011 - 11/2008)|
|5.||Doroshow, James H: 5 articles (09/2011 - 11/2008)|
|6.||Tomaszewski, Joseph E: 5 articles (09/2011 - 11/2008)|
|7.||Rodriguez, Luis E: 5 articles (12/2009 - 05/2007)|
|8.||Zhu, Gui-Dong: 5 articles (12/2009 - 05/2007)|
|9.||Luo, Yan: 5 articles (10/2009 - 05/2007)|
|10.||Nowsheen, Somaira: 4 articles (08/2014 - 01/2011)|
07/01/2011 - "That equivalent radiosensitization by ABT-888 plus IR in vitro failed to predict comparable results with tumors in vivo suggests that the efficacy of PARP inhibitors may partially depend on a competent senescence response to accumulated DNA damage."
11/01/2009 - "We aimed to determine whether the PARP inhibitor ABT-888 hits its therapeutic target in tumors by immunohistochemistry during a Phase 0 trial conducted at the National Cancer Institute. "
10/01/2009 - "Our study suggests that cancer cells upregulate the homologous recombination DNA repair pathway to compensate for the loss of base excision repair, which may account for the observed resistance to treatment with TMZ and ABT-888."
05/15/2007 - "We conclude that PARP-1 inhibition shows promise as an effective means of enhancing tumor sensitivity to radiation, and future clinical studies are needed to determine the potential of ABT-888 as a radiation enhancer."
08/01/2014 - "ABT-888 alone reduced orthotopic tumor growth by 51% in A2780ip2 cell line, predicted to respond by the ex vivo assay. "
|2.||Glioblastoma (Glioblastoma Multiforme)
05/15/2014 - "We have elucidated important factors controlling ABT-888 efficacy in glioblastoma. "
05/15/2014 - "Little is known about the optimal clinical use of ABT-888 (veliparib) for treatment of glioblastoma. "
05/15/2014 - "The potential of ABT-888 in glioblastoma can best be demonstrated in patients with PTEN null tumors. "
05/15/2014 - "ABT-888 is a PARP inhibitor undergoing extensive clinical evaluation in glioblastoma, because it may synergize with the standard-of-care temozolomide (TMZ). "
05/15/2014 - "ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy."
|3.||Colonic Neoplasms (Colon Cancer)
01/01/2015 - "When combined together, nontoxic concentrations of ABT-888 and VE-821 produced a 4.5-27 fold reduction in the IC50 of SN38 with the HCT-116 colon cancer cells demonstrating the highest sensitization as compared to LoVo and HT-29 colon cancer cells. "
04/01/2013 - "Using colon cancer cell lines significant synergy was observed between ABT-888 and irinotecan at concentrations of ABT-888 as low as 0.125 μM. "
04/01/2013 - "The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines."
04/01/2013 - "In conclusion this study suggests that ABT-888 may be a clinically effective adjuvant to current colon cancer therapies that include the use of irinotecan and/or oxaliplatin."
04/01/2013 - "As such, we hypothesized that colon cancers would be sensitized to the DNA damaging chemotherapeutic agents, oxaliplatin and irinotecan, by ABT-888. "
|4.||Gastrointestinal Neoplasms (Gastrointestinal Cancer)
03/01/2011 - "At the 2011 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, preclinical evidence was presented regarding the efficacy of C4 compound against focal adhesion kinase (FAK) (Abstract #214), the role of the cyclooxygenase-2 (COX-2) inhibitor apricoxib in enhancing the efficacy of gemcitabine and erlotinib (Abstract #227) and the role of curcumin and ABT-888 (a poly-ADP ribose polymerase (PARP) inhibitor) as potent radiosensitizers (Abstracts #222 and #203). "
|5.||Breast Neoplasms (Breast Cancer)
08/01/2014 - "Across a panel of BC and normal breast epithelial cell lines, the PARP1 inhibitor ABT-888 preferentially radiosensitizes breast cancer (vs. normal) cells with enhancement ratios (EnhR) up to 2.3 independent of intrinsic BC subtype or BRCA mutational status. "
09/15/2012 - "In addition, ABT-888 significantly inhibited NF-κB (p65/RelA) transcriptional activity in HER2+ but not HER2 negative breast cancer cells. "
07/01/2015 - "In this study, we investigated the antiproliferative effects and mechanism of PARP inhibitors ABT-888 (Veliparib), BSI-201 (Iniparib) and AZD228 (Olaparib) in breast cancer cell lines with BRCA1 or BRCA2 mutations and 9 different BRCA wild-type cell lines with BRCA1 allelic loss. "
12/01/2015 - "Moreover, curcumin, when combined with ABT-888, could effectively delayed breast tumor formation in vivo. "
03/13/2015 - "Moreover, ferulic acid, when combined with ABT-888, renders breast cancer cells become hypersensitive to ABT-888. "
|1.||Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
|7.||Cyclooxygenase 2 (Cyclooxygenase-2)
|8.||Focal Adhesion Protein-Tyrosine Kinases
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|4.||Homologous Transplantation (Allograft)